A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.

The invention provides genetic markers of severe suicidal behavior, related compositions, computer systems, and methods.

The application is about a method for diagnosing autism spectrum disorder (ASD) in a human subject, comprising providing a device comprising a reagent for determining the concentration of arginine vasopressin (AVP) in a biological sample from the subject; and measuring the concentration of AVP in the sample using the device. Disclosed is also a method for diagnosing ASD, comprising providing a first device comprising a reagent for determining a concentration of AVP and a second device comprising a reagent for determining a concentration of one or more analytes selected from arginine vasopressin receptor 1a and oxytocin receptor, to determine the concentrations of AVP and of the one or more analytes. Disclosed is also a method of predicting severity of ASD in a male human subject, comprising providing a device for determining the concentration of AVP in cerebrospinal fluid, said device comprising a reagent for determining presence or absence of AVP; and measuring the concentration of AVP in a biological sample from the subject using the device. Disclosed is also a method of predicting likelihood of an ASD in a human subject, comprising providing a device for determining the concentration of AVP in cerebrospinal fluid, said device comprising a reagent for determining presence or absence of AVP; and measuring the concentration of AVP in cerebrospinal fluid using the device.

Disclosed herein is a method for predicting or diagnosing psychiatric disorders through analyzing skin tissues samples minimally invasive or non-invasively collected. The method disclosed herein makes it possible to diagnose psychiatric disorders through objective biomarkers at a very early age, without giving pain to subjects because of noninvasive or minimally invasive feature of skin sample collection method.

The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.

The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).

The present invention relates to a method for treating autism spectrum disorders (ASD) or ASD-like symptom, particularly by administering a zinc ion source and/or a serine component e.g. D-serine or its precursor/analogue, optionally in combination with a mixture of branched-chain amino acids (BCAAs). The present invention also relates to a combination, kit or composition for performing the method for treatment as described herein. Further described is use of a zinc ion source and/or a serine component and optional BCAAs for manufacturing a medicament for treating a symptom or disease characteristics associated with ASD or ASD-associated disorder or as a food supplement for ameliorating relevant symptoms in a subject in need thereof. The present invention further provides an animal model for autistic spectrum disorder (ASD) with deficient CTTNBP2 gene, and a method for identifying an ingredient effective in the treatment of ASD by using such animal model.

The invention provides a method for determining a psychiatric disorder, as well as a marker for determining a psychiatric disorder, such as depressive disorder, bipolar disorder, schizophrenia, or dementia with high reliability (accuracy and precision). The method involves measuring amounts of (A) anthranilic acid and (B) tryptophan, kynurenine, or 3-hydroxyanthranilic acid in a sample, calculating a ratio of the amounts (A) and (B), and determining a psychiatric disorder based on the ratio of the amounts (A) and (B).

The present invention provides methods for diagnosing an autistic spectrum disorder (ASD), comprising detecting the concentration of an amino acid adduct in a sample obtained from a subject, wherein said amino acid adduct is a glycated amino acid adduct, an oxidised amino acid adduct, or a nitrated amino acid adduct. Methods of the invention further comprise comparing the concentration of the amino acid adduct in the sample with the concentration of the same amino acid adduct in a reference standard; and identifying the presence or absence of a concentration difference of said amino acid adduct in the sample relative to the reference standard; wherein the presence or absence of a concentration difference correlates with the presence or absence of ASD. Diagnostic algorithms for use in methods of the invention are also provided.

The present invention features methods of detecting the level of inositol trisphosphate receptor (IP.sub.3R) free calcium (Ca.sup.2+) signaling activity in the cultured cells induced by an agonist of IP.sub.3R Ca.sup.2+ signaling. The detection of IP.sub.3R Ca.sup.2+ signaling allows for diagnosing the risk of a patient or subject for developing an Autism Spectrum Disorder (ASD). Additionally, methods described herein could be used for identifying potential therapeutic anti-ASD agents. The methods for treatment and monitoring of the disease are also outlined.